Devyser

Operating in the global genetic diagnostics market, Devyser serves clients in over 65 countries. The business model is centered on the sale of diagnostic kits and services, primarily through a direct sales organization in 17 countries, which accounts for approximately 77% of sales, and a network of distributors for the remaining 23%. In 2022, Devyser expanded its presence in the U.S. by establishing its own CLIA-certified laboratory in Atlanta, Georgia, to offer test services directly to American customers, manage reimbursement, and foster closer relationships with physicians and patients. The company also generates revenue through commercial partnerships, such as the one with Thermo Fisher Scientific for the distribution of its post-transplant monitoring products.

Devyser specializes in diagnostic solutions for oncology, hereditary diseases, and transplantation. The product portfolio includes Next-Generation Sequencing (NGS) and PCR-based kits designed for ease of use, often employing a single-tube assay to streamline laboratory processes. Key product areas are post-transplant monitoring for graft rejection, hereditary cancer screening (e.g., Devyser BRCA NGS), reproductive health for aneuploidy analysis, and testing for genetic conditions like cystic fibrosis and thalassemia. The company's primary focus is on NGS tests, which offer high throughput and cost-effectiveness. All NGS products are complemented by dedicated software for data analysis. A significant milestone was achieved in December 2021 when Devyser was listed on the Nasdaq First North Premier Growth Market in Stockholm, raising approximately SEK 343 million.